|By PR Newswire||
|April 3, 2014 08:02 AM EDT||
NEW YORK, April 3, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Johnson & Johnson Analyst Notes
On March 31, 2014, Johnson & Johnson announced that it has accepted the binding offer from The Carlyle Group. According to the release, the binding offer was received and announced on January 16, 2014, to acquire the Company's Ortho-Clinical Diagnostics business for approximately $4 billion, subject to customary adjustments. Additionally, the Company stated that the acceptance was made after consultation with the relevant works councils and trade unions. Johnson & Johnson also stated that the transaction is expected to close towards the middle of the year, upon satisfaction of customary closing conditions and that it will discuss any updates on the transaction during its scheduled quarterly earnings call on April 15, 2014. The full analyst notes on Johnson & Johnson are available to download free of charge at:
Teva Pharmaceutical Industries Limited Analyst Notes
On March 31, 2014, Teva Pharmaceutical Industries Limited (Teva) announced that its COPAXONE® certiorari petition has been granted by the U.S. Supreme Court and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (808 patent). According to the release, the 808 patent expires on September 1, 2015, and claims a process for manufacturing the active ingredient of the Company's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE® (glatiramer acetate injection) 20mg/L. Additionally, the Company stated that it has previously prevailed in the District Court regarding nine COPAXONE® patents, including the 808 patent. Teva also stated that any purported generic version of COPAXONE® would be required to obtain the Food and Drug Administration's (FDA) approval prior to being made available to the public. The full analyst notes on Teva Pharmaceutical Industries Limited are available to download free of charge at:
Celgene Corporation Analyst Notes
On March 23, 2014, Celgene Corporation (Celgene) announced that it has released new research findings on OTEZLA® (apremilast) from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) in Denver, CO. According to Celgene, in ESTEEM 1 and 2, patients were given OTEZLA 30mg twice daily (BID) or placebo for the first 16 weeks, then followed by a maintenance phase through week 32, in which patients on placebo for 16 weeks were switched to OTEZLA. Additionally, the Company stated that patients initially randomized to OTEZLA 30 mg BID, and those who were PASI 75 (Psoriasis Area and Severity Index) responders at week 32, were re-randomized to either OTEZLA 30mg BID or placebo. Commenting on the news, Jennifer Cather, M.D., Modern Research Associates, Dallas Texas, stated, "Results from the 52-week analysis of the ESTEEM program suggest that early responses seen with OTEZLA treatment in multiple efficacy endpoints of plaque psoriasis, including difficult to treat areas, are durable over time. Together with the observed long-term consistent safety and tolerability profile, these findings are encouraging." The full analyst notes on Celgene Corporation are available to download free of charge at:
Cara Therapeutics Inc. Analyst Notes
On March 31, 2014, Cara Therapeutics Inc.'s (Cara Therapeutics) stock went up by 12.65%, at $18.61 per share. For the past three-month trading period, Cara Therapeutics' shares reflected an increase of 44.14%, compared to the Nasdaq Composite which went up by 2.31% over the same three-month trading period. The full analyst notes on Cara Therapeutics Inc. are available to download free of charge at:
OncoMed Pharmaceuticals, Inc. Analyst Notes
On March 31, 2014, OncoMed Pharmaceuticals, Inc.'s (OncoMed Pharmaceuticals) stock went up by 15.87%, at $33.65 per share. Over the past six-month trading period, the Company's stock increased significantly by 119.79%, compared to the Nasdaq Composite which went up by 11.33% during the same trading session. The full analyst notes on OncoMed Pharmaceuticals, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
ReadyTalk has expanded the capabilities of the FoxDen collaboration platform announced late last year to include FoxDen Connect, an in-room video collaboration experience that launches with a single touch. With FoxDen Connect, users can now not only engage in HD video conferencing between iOS and Android mobile devices or Chrome browsers, but also set up in-person meeting rooms for video interactions. A host’s mobile device automatically recognizes the presence of a meeting room via beacon tech...
Jul. 29, 2016 12:15 PM EDT
Jul. 29, 2016 12:00 PM EDT Reads: 1,824
Jul. 29, 2016 12:00 PM EDT Reads: 2,088
Jul. 29, 2016 11:46 AM EDT Reads: 199
Jul. 29, 2016 11:30 AM EDT Reads: 1,230
Jul. 29, 2016 11:15 AM EDT Reads: 668
Jul. 29, 2016 11:15 AM EDT Reads: 1,333
Jul. 29, 2016 11:00 AM EDT Reads: 785
Jul. 29, 2016 11:00 AM EDT Reads: 420
Jul. 29, 2016 11:00 AM EDT Reads: 495
Jul. 29, 2016 11:00 AM EDT Reads: 513
Jul. 29, 2016 10:53 AM EDT Reads: 270
Jul. 29, 2016 10:45 AM EDT Reads: 491
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Jul. 29, 2016 09:45 AM EDT Reads: 2,127
Jul. 29, 2016 09:45 AM EDT Reads: 1,029